Fluvoxamine for the treatment of COVID-19 - Author's reply
Lancet Glob Health
.
2022 Mar;10(3):e333.
doi: 10.1016/S2214-109X(21)00588-X.
Authors
Gilmar Reis
1
,
Edward Mills
2
Affiliations
1
Gilmar Reis, Cardresearch - Cardiologia Assistencial e de Pesquisa, Brazil.
2
Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON L8S 4K1, Canada. Electronic address: millsej@mcmaster.ca.
PMID:
35180413
PMCID:
PMC8846598
DOI:
10.1016/S2214-109X(21)00588-X
No abstract available
Publication types
Letter
Comment
MeSH terms
COVID-19 Drug Treatment*
Fluvoxamine / therapeutic use
Humans
SARS-CoV-2
Substances
Fluvoxamine